// 廣州銳合基因科技完成了一筆1500萬美元的B輪融資，用於其基因編輯候選藥物組合的研發，包括一種針對地中海貧血的臨床階段治療方案。 在一項I期臨床試驗中，該公司的首個β地中海貧血基因編輯藥物RM-001取得了100%的治癒率。 此外，銳合還在眼科、神經系統和其他領域開發體內基因編輯療法，用於治療重要的遺傳性疾病。
Guangzhou Reforgene Biotechnology closed a $15 million Pre-B financing for its portfolio of gene editing candidates, including a clinical stage therapy for thalassemia. In a Phase I trial, the company’s lead β-thalassemia gene-editing drug, RM-001, produced a 100% cure rate. In addition, Reforgene is developing in vivo gene editing therapies for major genetic diseases in the fields of ophthalmology, nervous system and other fields. https://chinabio.ssl.subhub.com/articles/reforgene-15-million //